©The Author(s) 2026.
World J Psychiatry. Feb 19, 2026; 16(2): 112462
Published online Feb 19, 2026. doi: 10.5498/wjp.v16.i2.112462
Published online Feb 19, 2026. doi: 10.5498/wjp.v16.i2.112462
Table 2 Study description
| Ref. | Study design | Patients/ECT sessions | R dose | SG dose | SCC dose | Induction agent | Key outcomes measured |
| Hoshi et al[11] | Small observational case series, non-blinded muscle relaxant selection | 5 patients (every patient 3 with SCC and 4 with R + SCC) | 0.6 mg/kg | 16 mg/kg | 1 mg/kg | Propofol 1.0 mg/kg | T1 10% and 90% recovery, time to first spontaneous breath, eye opening, seizure duration, adverse effects |
| Kadoi et al[12] | Clinical study, lottery system for sugammadex dose (non-blinded sugammadex administration) | 17 patients(3 session with different dose of SG and 4 sessions of SCC) | 0.6 mg/kg | 16 mg/kg, 8 mg/kg, or 4 mg/kg | 1 mg/kg | Propofol 1.0 mg/kg | T1 10% and 90% recovery, seizure duration, time to first spontaneous breath, adverse effects |
| Saricicek et al[13] | Randomized | 45 patients | 0.3 mg/kg | 4 mg/kg | 1 mg/kg | Propofol 1 mg/kg | Myalgia VAS, headache VAS, time to T1, T2, motor seizure duration |
| Koksal et al[14] | Randomized, double-blind (for drug preparation) | 16 patients | 0.6 mg/kg | 4 mg/kg | 1 mg/kg | Propofol 2 mg/kg | Spontaneous breathing time, eye opening time, time for obeying instructions, motor seizure duration, MAS and MAS 9 timing, T1 0% and T1 90% times, vital signs, side effects |
| Oflezer et al[15] | Single-center retrospective observational study | 134 patients | 0.3 mg/kg | 2 mg/kg | 0.5 mg/kg | Propofol 1 mg/kg | EEG seizure duration, motor seizure modification, CGI-I score, adverse effects, vital signs |
| Moutaoukil et al[16] | Small observational case series (prospectively collected) | 4 patients | 0.3 mg/kg | 4 mg/kg | 0.5 mg/kg | Propofol 1-1.5 mg/kg | Motor seizure modification, time to spontaneous breathing, time to eye opening, agitation, myalgia, headache, nausea/vomiting, EEG seizure duration |
| Karaca Bent et al[17] | Single-center observational cohort study (prospective collection, retrospective analysis) | 100 adult patients | 0.4 mg/kg | 2 mg/kg | 1 mg/kg | Propofol 1 mg/kg | Spontaneous breathing time, spontaneous eye opening, seizure duration, vital signs (BP, HR, SpO2) |
- Citation: Anand R, Nag DS, Gope RL, Sahoo MK, Bhushan P, Pal BD, Patel R, Shivani S, Bharadwaj MK, Ansari MA. Rocuronium-sugammadex as an alternative muscle relaxant to succinylcholine in electroconvulsive therapy: A meta-analysis. World J Psychiatry 2026; 16(2): 112462
- URL: https://www.wjgnet.com/2220-3206/full/v16/i2/112462.htm
- DOI: https://dx.doi.org/10.5498/wjp.v16.i2.112462